Journal of Clinical Densitometry
Volume 13, Issue 1 , Pages 1-9 , January 2010

2009 Santa Fe Bone Symposium

  • E. Michael Lewiecki

      Affiliations

    • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
    • Corresponding Author InformationAddress correspondence to: E. Michael Lewiecki, MD, FACP, FACE, New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106.
    • ,
  • John P. Bilezikian

      Affiliations

    • Columbia University College of Physicians and Surgeons, NYC, NY, USA
    • ,
  • Andrew J. Laster

      Affiliations

    • Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, USA
    • ,
  • Paul D. Miller

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO, USA
    • ,
  • Robert R. Recker

      Affiliations

    • Creighton University School of Medicine, Omaha, NE, USA
    • ,
  • R. Graham G. Russell

      Affiliations

    • The Botnar Research Centre, University of Oxford, Oxford, UK
    • ,
  • Michael P. Whyte

      Affiliations

    • Washington University School of Medicine, St. Louis, MO, USA

Received 16 November 2009 ,Revised 14 December 2009 ,Accepted 14 December 2009.

References 

  1. Lewiecki EM, Baim S, Bilezikian JP, et al. 2008 Santa Fe Bone Symposium: update on osteoporosis. J Clin Densitom. 2009;12(2):135–157
  2. Lewiecki EM, Bilezikian JP, Cooper C, et al. Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. J Clin Densitom. 2008;11(2):313–324
  3. Lewiecki EM. 2006 Proceedings of the Santa Fe Bone Symposium. Women's Health. 2006;2(6):825–828
  4. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262–1264
  5. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165:1264–1266
  6. Fleisch H, Russell RG, Simpson B, Muhlbauer RC. Prevention by a diphosphonate of immobilization “osteoporosis” in rats. Nature. 1969;223(5202):211–212
  7. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–759
  8. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 Suppl):S14–S21
  9. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122(2 Suppl):S22–S32
  10. Bilezikian JP, Matsumoto T, Bellido T, et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2009;24(3):373–385
  11. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–916
  12. Bilezikian JP, Rubin MR. Monitoring anabolic treatment. In: Seibel MJ, Robins SP, Bilezikian KJP editor. Dynamics of Bone and Cartilage Metabolism. 2nd ed. San Diego, CA: Elsevier Academic Press; 2006;p. 629–647
  13. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441
  14. Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(10):1663–1673
  15. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58(6):1687–1695
  16. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18–22
  17. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res. 2007;22:1832–1841
  18. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–831
  19. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765
  20. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone. 2009;44(2):199–207
  21. McClung M, Bone H, Cosman F, et al. A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24 month results. J Bone Miner Res. 2008;23(Suppl 1):S82
  22. Lane NE, Cosman F, Bolognese M, et al. Transdermal delivery of hPTH (1-34) (ZP-PTH) is effective in increasing bone mineral density of the lumbar spine and hip in postmenopausal women with osteoporosis. Arthritis Rheum. 2008;9(Suppl 1):2
  23. Fitzpatrick LA, Brennen E, Kumar S, et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J Bone Miner Res. 2008;23(Suppl 1):S50
  24. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13(4):485–496
  25. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578–588
  26. Padhi D, Stouch B, Jang B, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res. 2007;22(Suppl 1):S37
  27. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003;18(7):1227–1234
  28. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85(8):2907–2912
  29. Reid DM, Hughes R, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res. 2000;15:1006–1013
  30. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363–1374
  31. Massry SG, Coburn JW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S10–S135
  32. Hruska KA, Mathew S, Lund RJ, et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol. 2009;29(2):156–165
  33. Moe SM, Drueke TB for the KDIGO Working Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1–S128
  34. Miller PD. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol. 2009;29(2):144–155
  35. Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167(2):133–139
  36. Sprague SM. Renal function and risk of hip and vertebral fractures in older women: is it always osteoporosis?. Arch Intern Med. 2007;167(2):115–116
  37. Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res. 2007;22(2):203–210
  38. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002;17(12):2094–2105
  39. Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S140–S150
  40. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–2115
  41. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503–508
  42. Miller PD. Is there a role for bisphosphonates in chronic kidney disease?. Semin Dial. 2007;20(3):186–190
  43. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385–1393
  44. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377–387
  45. National Kidney Disease Education Program . GFR calculators. National Kidney Disease Education Program. Available at: http://www.nkdep.nih.gov/professionals/gfr_calculators/index.htmAccessed: November 8, 2009
  46. Martin TJ. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J Musculoskelet Neuronal Interact. 2004;4(3):243–253
  47. Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45–48
  48. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002;17(1):26–29
  49. Whyte MP, Reinus WR, Podgornik MN, Mills BG. Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred. Medicine (Baltimore). 2002;81(2):101–121
  50. Siris ES. Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions. Semin Arthritis Rheum. 1994;23(4):222–225
  51. Meunier PJ, Coindre JM, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum. 1980;23(10):1095–1103
  52. Paget J. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans. 1877;60:37–63
  53. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest. 2005;115(2):200–208
  54. McKusick VA. Heritable disorders of connective tissue. 2nd ed. St. Louis, MO: Mosby; 1960;
  55. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582–1588
  56. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377–381
  57. Good DA, Busfield F, Fletcher BH, et al. Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet. 2002;70(2):517–525
  58. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347(3):175–184
  59. Department of Health and Human Services. 2006 CMS-1321-FC. Federal register.
  60. Department of Health and Human Services. 2006 CMS-1512-PN. Federal register.
  61. Department of Health and Human Services. 2009 CMS-1431-P. Federal register.
  62. Department of Health and Human Services. 2007 CMS-1385-FC. Federal register.
  63. The Lewin Group . Assessing the costs of performing DXA services in the office-based setting (survey data report prepared for American Association of Clinical Endocrinologists. International Society for Clinical Densitometry, The Endocrine Society, and American College of Rheumatology). The Lewin Group. Available at: http://www.endo-society.org/publicpolicy/legislative/upload/DXA_Final_Report_from_The_Lewin_Group10_31_07.pdf2007;Access date is August 2, 2009
  64. Curtis JR, Laster A, Becker DJ, et al. The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. Osteoporos Int. 2009;20(9):1553–1561

PII: S1094-6950(09)00272-8

doi: 10.1016/j.jocd.2009.12.003

Journal of Clinical Densitometry
Volume 13, Issue 1 , Pages 1-9 , January 2010

Article Tools